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A dramatic evolution has occurred in the past four decades in our underlying knowledge of
pathophysiology of the hypertensive diseases and in the availability of myriad pharmacologic
agents for control of hypertension. This report provides a current review of antihypertensive
treatment interspersed with personal opinions supported by appropriate references. It focuses
on the recent national recommendations dealing with the prevention, detection, evaluation
and treatment of the disease (JNC-6). Whereas I believe that the height of arterial pressure
is of primary importance, it is not the sine qua non explaining all target organ involvement
or complications of hypertensive disease. Consequently, all that is classified today as Stages 1
and 2 hypertension (old terminology: “mild” and “moderate”) in terms of blood pressure
elevation does not explain all outcomes of disease. Indeed, JNC-6 introduced the new concept
of risk stratification for therapy based not only on the height of systolic and diastolic pressure
but also on the presence of target organ involvement, comorbidity and other risk factors.
However, after considerable advances since the inception of the National High Blood
Pressure Education Program (NHBPEP) in 1972, it appears that we are avoiding our
responsibilities and reversing our gains. It is of vital importance that we renew our efforts to
identify, evaluate and treat all patients with hypertension; this is especially so for the vast
numbers of patients with Stages 1 and 2 hypertension. (J Am Coll Cardiol 1999;34:
1369–77) © 1999 by the American College of Cardiology
The National High Blood Pressure Education Program
(NHBPEP) was established in 1972 by then Secretary of
the Department of Health and Human Welfare, Eliot
Richardson, on the recommendation of Theodore E.
Cooper, M.D., Assistant Secretary for Health, and Mrs.
Mary Lasker. It was in that year that Edward D.
Freis, M.D., Senior Medical Investigator of the Veterans
Administration, received the Lasker Award for his land-
mark Veterans Administration Cooperative Studies which
first demonstrated the safety and efficacy of antihypertensive
therapy. Over the ensuing 27 years, the Joint Coordinating
Committee of the NHBPEP has provided the leadership in
educating the public and the healthcare professions about
the necessity for detecting, evaluating and treating patients
with hypertension. The centerpiece of this education pro-
gram has been the succession of Joint National Committee
reports (now in its sixth printing) (1) and many other
important working papers concerned with the multitude of
aspects of the hypertension problem (from hypertensive
diseases in special populations to specific reports related to
the unique problems of specific target organ involvement
from hypertensive disease, to other related issues dealing
with hypertension in the workplace, problems of adherence
to antihypertensive therapeutic programs) and others.
Moreover, this novel national health education program has
served as the template for other important national health
education programs by the National Heart, Lung, and
Blood Institute (e.g., cholesterol, asthma, smoking).
The result of the NHBPEP has been a greater awareness
of the need to initiate treatment of patients with hyperten-
sion and the establishment of other national hypertension
programs throughout the world. Great gains have been
accomplished in society with the recognition of those
patients with more severe stages of the disease and, as a
result, fewer patients currently present to their physicians or
to hospitals with severe hypertensive emergencies. The
mortality rates from stroke and coronary heart disease
continue to fall (1). Most patients currently have hyperten-
sive disease of lesser severity and most of these people go
either unrecognized, untreated or their blood pressures
remain uncontrolled until the complications of the disease
appear. Formerly, these patients were said to have “mild
hypertension” because the severity of their disease was
obviously far less than those patients who presented in large
numbers with much more severe disease in the earlier years.
This review was written with this concern in mind and with
the hope that more patients with earlier stages of hyperten-
sion would be recognized and would be better treated then
they are today (1). It is hoped that the benefits to be reaped
will be a break in the ever-increasing curves indicating a
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progressive rise in cardiac failure and end stage renal disease
resulting from hypertension.
Several issues must be addressed before discussing treat-
ment of these patients with less severe stages of hyperten-
sion. The first is that detection, evaluation and treatment of
patients with hypertension have been less successful in
recent years. At the outset of NHBPEP in 1972, only 12%
of patients were aware of their hypertension, under treat-
ment and with pressures controlled. Through the efforts of
this program, the number of patients with controlled pres-
sures increased significantly. However, recent data indicate
an appalling reversal (Table 1) (1,2). Most patients with
hypertension have systolic or diastolic pressures falling
between 140 to 159 and 90 to 99 mm Hg, respectively.
They may also have target organ involvement, yet they may
be included in what heretofore was termed “mild” (presently
termed “Stages 1 and 2”) hypertension (Table 2). Many of
these patients have isolated borderline systolic pressure
elevation (140 to 159 mm Hg), a level that still requires
prospective controlled studies to demonstrate efficacy of
pressure reduction (3). They should benefit from antihyper-
tensive therapy, and their disease should be deterred from
progressing to further target organ involvement or death.
Second, primary prevention of hypertension is feasible
(4). Thus, in 1988, approximately 59 million Americans had
hypertension (5), but recent reports estimate that this
number has diminished to about 43 million (4,6). Explana-
tion for this decrease has been attributed, at least in part, to
the active interest of the general public with either “high
normal” or Stage I hypertension and who participated in
their overall wellness by lifestyle modifications. These in-
terventions have been effective in reducing lesser elevated
blood pressure levels to normotensive levels (4).
The third issue is that, until publication of the national
recommendations dealing with the prevention, detection,
evaluation and treatment of hypertension (JNC-5 and
JNC-6), classification of hypertension only considered in-
dividuals with diastolic pressures between 89 and
105 mm Hg (i.e., “mild” hypertension). Even in JNC-5,
“mild” hypertension included patients whose systolic and
diastolic pressures were 140 to 159 or 90 to 99 mm Hg,
respectively (5). Because these patients with lower pressure
elevations are at risk for increased morbidity and mortality,
continued use of the term “mild” conveyed the wrong
message to these affected individuals and their physicians.
This discussion primarily concerns treatment of patients
with Stages 1 and 2 hypertension. We also emphasize
attention to those people with “high” normal systolic or
diastolic pressures (i.e., 130 through 139 or 85 through
89 mm Hg, respectively) because these individuals are also
at increased risk requiring clinical management (Table 2).
A fourth point is that JNC-6 was carefully intended to be
“evidence based” (1). However, recommendations in the
first five reports were also based on findings of large
controlled, multicenter trials, many of which were placebo-
controlled. This discussion concerns information published
in JNC-6 and thereafter. Finally, for the first time,
JNC-6 recommended setting therapeutic goal pressures
(usually ,140/,90 mm Hg) for most patients, but
,130/,85 mm Hg in diabetics.
RISK STRATIFICATION
I believe that one important innovation of JNC-6 having
particular pertinence for patients with high normal blood
pressure or with Stage 1 hypertension is risk stratification
and its value in formulating antihypertensive treatment.
These individuals have the greatest likelihood either of
developing more severe hypertension or complications from
hypertension and other cardiovascular diseases. Inherent in
risk stratification is proper measurement of blood pressure,
determination of other risk factors (Table 3) and evaluation
for target organ damage or other clinical evidence of
Abbreviations and Acronyms
ACE 5 angiotensin converting enzyme
ARB 5 angiotensin II (type I) receptor
blocker
CHD 5 coronary heart disease
ESRD 5 end stage renal disease
JNC-5 and JNC-6 5 national recommendations dealing
with the prevention, detection,
evaluation and treatment of
hypertensive disease
MI 5 myocardial infarction
NHBPEP 5 National High Blood Pressure
Education Program
Table 1. Trends in Awareness, Treatment and Control of High
Blood Pressure in Adults: U.S., 1976–1994 (1)
NHANES II
(1976–80)
NHANES III
(Phase 1)
1988–91
NHANES III
(Phase 2)
1991–94
Awareness 51% 73% 68.4%
Treatment 31% 55% 53.6%
Control* 10% 29% 27.4%
*Systolic and diastolic pressures under 140 and 90 mm Hg, respectively.
Table 2. Classification of Blood Pressure for Adults Aged 18
and Older (1)
Category
Systolic
(mm Hg)
Diastolic
(mm Hg)
Optimal 120 and 80
Normal 130 and 85
High-normal 130–139 or 85–89
Hypertension
Stage 1 140–159 or 90–99
Stage 2 160–169 or 100–109
Stage 3 180 or 110
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cardiovascular disease (Table 4). These factors should be
assessed carefully by medical history, physical examination
and laboratory investigations when the patient is first
evaluated and thereafter. From this information patients are
categorized into risk groups depending on whether there is
target organ involvement or other diseases (Table 5). For
the purpose of this discussion, I have added additional risk
factors. The JNC-6 acknowledged obesity as a risk factor,
but stated that it was “of less significance in the selection of
antihypertensive drugs” (1). Treatment with weight reduc-
tion measures is of primary importance (7,8). However,
recidivism is prevalent; therefore, emphasizing the need for
antihypertensive therapy is highly significant (9–11), par-
ticularly if pharmacologic means for managing obesity
become available. Hyperhomocysteinemia has received re-
cent emphasis as a major risk factor (12), requiring folic acid
treatment (13). Hyperuricemia is frequently cited as a
cardiovascular risk factor (14,15). Moreover, there is abun-
dant evidence indicating its presence in most untreated
hypertensive patients (16), and it also provides an index of
early renal involvement in hypertension (17–19). Because
angina pectoris may be present in patients with only
hypertensive heart disease, in this discussion I dissociate this
manifestation of cardiac involvement (Table 4) from a
history of myocardial infarction (MI) (20–23). Further-
more, patients with a history of renal arterial disease
(particularly with atherosclerotic lesions) should also be
considered as having significant clinical cardiovascular dis-
ease. Each of these factors provides a real basis in selecting
treatment.
LIFESTYLE MODIFICATIONS
As indicated in the risk stratification table for selecting
treatment, in some patients nonpharmacologic interventions
are of proved value (Table 5). This is best exemplified in
individuals with high-normal pressures, because primary
prevention in essential hypertension has already been dem-
onstrated in them (1,4,9,11). Among the various lifestyle
modification strategies effective in controlling elevated ar-
terial pressure are: weight control for those who are 15
percent over ideal body weight, restriction of daily ethanol
intake to no more than one ounce per day, reduction of daily
sodium intake to 2.4 g and involvement in a regular aerobic
exercise program (e.g., 30 to 45 min several days each week).
Special mention must be made to emphasize the necessity to
discontinue cigarette smoking. This advice not only pertains
to overall cardiovascular health, but also for antihypertensive
therapy. Experience from the Medical Research Council
(Great Britain) and Australian Mild Hypertension Trials
have shown that individuals who smoke and take beta-
adrenergic blocking agents (beta-blockers)—even if pres-
sure is controlled to the same levels achieved with a
diuretic—do not have the same protection from stroke and
MI that is conferred by a diuretic (24,25). Other lifestyle
measures recently shown to be of value include maintenance
of adequate potassium intake (approximately 90 mmol per
day) (26) and, perhaps, of magnesium (27). Rationale for
these interventions has been detailed earlier (1,11,28), and
will not be detailed herein. Other lifestyle interventions for
hypertension treatment have been suggested, but they have
not yet been adequately shown to be effective.
PHARMACOLOGIC TREATMENT
Uncomplicated hypertension. In general, JNC-6 recom-
mends that the thiazides and beta-blockers are best indi-
cated for the uncomplicated patient with essential hyper-
tension. These agents should be prescribed initially in less
than full doses (e.g., 12.5 or 25 mg for hydrochlorothiazide
and 25 mg for atenolol, as examples); they may then be
increased to full doses (25 or 50 mg) if pressure is not
controlled optimally (i.e., less than 140 or 90 mm Hg,
systolic or diastolic, respectively) (1). Since JNC-6 publica-
tion, a question has been raised as to recommendation of
beta-blockers, suggesting they may not be of value (29).
This observation had been considered in JNC-6, and it has
eliminated beta-blockers from recommendation in elderly
Table 3. Cardiovascular Risk Factors
Smoking Age (older than 60 years)
Obesity* Gender (men, postmenopausal
women)
Diabetes mellitus Family history of cardiovascular
disease (women 65 or men 55 yrs)
Hyperlipidemia
Hyperhomocysteinemia*
Hyperuricemia*
These risk factors have been modified by the author from JNC-6 (1) and also include
other factors (identified by the author with an asterisk*) that have been demonstrated
to add additional risk.
Table 4. Evidence of Target Organ Damage or Other
Cardiovascular Disease
Cardiac involvement:
Left ventricular hypertrophy
Cardiac failure
Angina pectoris*
Prior myocardial infarction
History of coronary revascularization or percutaneous coronary
angioplasty*
Arterial involvement:
Aortic aneurysmal disease*
Peripheral vascular disease
Brain involvement:
Stroke
Transient ischemic attack
Hypertensive retinopathy
Renal involvement:
Nephrosclerosis*
Prior renal arterial disease*
Modified from JNC-6 (1) by the author to include additional diseases as indicated by
an asterisk*. See text for discussion.
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patients with isolated systolic hypertension (1,30). Never-
theless, the beta-blockers had been shown to be of value in
studies of younger patients, particularly with diastolic pres-
sure elevation (5,31,32). Of course, there are some patients
whose blood pressures do not respond to either of these
agents, and other drugs must be used.
I believe that the JNC-6, is a guideline, not to be
construed as an absolute recommendation. It provides a
straightforward means for selecting therapy in a cost-
effective fashion, but there is a wide laterality for flexibility.
Since promulgation of JNC-6, several randomized, con-
trolled, multicenter studies have been conducted comparing
the efficacy of several agents with diuretics. Thus, verapamil
demonstrated efficacy similar to chlorthilidone, but the
diuretic produced more hyperuricemia and hyperkalemia
than verapamil which was more effective in diminishing
carotid wall thickness (33,34). As indicated, there are
certain compelling reasons for using classes of antihyperten-
sive agents other than diuretics and beta-blockers; not every
hypertensive patient needs be treated with these two drug
classes. Consider the patient with Stage 1 or 2 hypertension
with marked bradycardia. That patient may not respond or
may have had side effects of a diuretic or an angiotensin
converting enzyme (ACE) inhibitor mitigating their use.
For the same reason that a beta-blocking agent cannot be
administered, certain calcium antagonists (e.g., verapamil,
diltiazem) may not be prescribed. Thus, there may be
compelling reasons to select a dihydropyridine calcium
antagonist. Whereas these compelling indications may not
be very common, these and other mitigating clinical situa-
tions can occur with sufficient frequency in uncomplicated
patients with hypertension to justify their use as well as new
classes of agents yet to be developed.
COMPELLING INDICATIONS
Several “compelling indications” cited in JNC-6 provide
exceptions to initial use of diuretics or beta-blockers. These
citations suggest other means for treating hypertensive
patients with diabetes mellitus, cardiac failure, MI or
isolated systolic hypertension, many of whom have Stage 1
or 2 pressure elevation (1). I believe that other compelling
reasons exist, some of which were included in JNC-6 as
“special indications.” I am not completely sure of this
semantic differentiation, although certain comorbid diseases
may preferentially merit the use of a diuretic or beta-blocker
for both the hypertension and the other disease. The
following discussion details the rationale for use of other
drug classes for initial therapy of Stage 1 or 2 hypertensive
patients. Some concepts are consistent with JNC-6 recom-
mendations; others may either have been published since
JNC-6 promulgation or are my point of view, supported by
appropriate citations.
Coronary heart disease. Rather than use the terms angina
pectoris or MI, I have suggested the broader concept of
coronary heart disease (CHD) for several reasons. First, and
perhaps most important, we must recognize that the earlier
and more recent controlled studies employed the term
CHD as a major end point (1,35). Mortality from CHD (in
these studies) included not only mortality from MI, but also
from unstable or unremitting angina pectoris, sudden car-
diac death, lethal cardiac failure, lethal dysrhythmias or
unexplained death unsupported by autopsy. This is impor-
tant to understand because these deaths may result from
hypertensive heart disease alone or be associated with
occlusive atherosclerotic epicardial coronary arteries (20–
22). Hypertensive heart disease, without significant coexis-
tent coronary arterial atherosclerosis, may be explained
hemodynamically by several mechanisms including: in-
creased coronary arterial resistance and minimal resistance,
reduced coronary blood flow and flow reserve and increased
blood viscosity. These alterations occur experimentally in
rats with genetically induced hypertension (36,37) and in
essential hypertensive patients with left ventricular hyper-
trophy (38–42). Implicit in the importance of these alter-
ations is increased left ventricular tension and myocardial
oxygen demand, ventricular fibrosis (with collagen deposi-
tion) and endothelial dysfunction of the coronary vascula-
ture and myocardium (43,44). The natural history, then, of
hypertensive heart disease (even in Stages 1 and 2 patients)
may terminate in sudden death, dysrhythmias, impaired
systolic or diastolic function and ventricular failure and
myocardial microinfarction(s) (45). With coexistent occlu-
sive epicardial atherosclerotic coronary arterial disease, there
is exacerbated CHD with its inherent outcomes.
Diuretic therapy without adequate protection from sec-
ondary hypokalemia increases the likelihood of dysrhyth-
mias and sudden death (46). Much of this enhanced risk
may be attenuated by administration of supplemental po-
Table 5. Risk Stratification and Antihypertensive Treatment Selection
Hypertension Stages (mm Hg)
Risk Group A
Risk Group B
Risk Group C
No Risk Factor
No TOI/CCD
At Least 1 Risk Factor,
excluding Diabetes Mellitus
No TOI or CCD
TOI, CCD or Diabetes or
Other Risk Factors
High normal (130–139/85–89) Lifestyle modification Lifestyle modification Drug therapy
Stage 1 (140–159/90–99) Lifestyle modification Lifestyle modification Drug therapy
Stages 2 and 3 (,160/,100) Drug therapy Drug therapy Drug Rx
CCD 5 clinical evidence of cardiovascular disease; TOI 5 target organ involvement.
1372 Frohlich JACC Vol. 34, No. 5, 1999
Mild Hypertension Treatment November 1, 1999:1369–77
tassium, potassium-sparing agents or low-dose diuretics
(47). Thus, when low-dose thiazides were used in multi-
center studies, the 26% reduction in CHD deaths, initially
predicted by the earliest meta-analysis (in which a signifi-
cant 14% was achieved) (35), was confirmed (48), and this
was achieved in elderly patients.
Without adequate control of pressure and left ventricular
afterload, increased myocardial oxygen demand results.
Beta-blockers have been shown to be safe and effective in
patients with angina pectoris (with or without atheroscle-
rosis) as a result of their ability to reduce pressure, heart rate,
left ventricular mass and myocardial metabolic oxygen
demand (49–51). If these agents prove inadequate, calcium
antagonists may be used if the agent selected does not
adversely compromise chronotropic and inotropic myocar-
dial function. These provisions are included in JNC-6 but,
in addition, ACE inhibitors alone or with angiotensin II
(type 1) receptor blockers (ARBs) may be of value. Exper-
imental and clinical studies have reported that these two
classes of antihypertensive agents are capable of increasing
coronary blood flow and flow reserve, thereby improving the
altered coronary hemodynamics associated with hyperten-
sive heart disease (36,52). Experimental (and early clinical)
studies have indicated that these compounds improve en-
dothelial dysfunction explainable by reduced ACE- and
chymase-generated angiotensin II, increased bradykinin (by
ACE inhibitors), increased nitric oxide generation and
other effects of ACE inhibition (e.g., PAI-1 inhibition of
intravascular thrombosis, anti-inflammatory factors) (53–
55). Additionally, the literature is replete with data from
many studies in which ACE inhibitors were given to
patients following MI demonstrating reduction in deaths,
prevention of subsequent MI and preventing or ameliorat-
ing cardiac failure (54–58). Hence, abundant data exist to
support the use not only of beta-blockers and calcium
antagonists for patients with hypertension with CHD, but
also for ACE inhibitors and ARB’s. If the ACE-inhibitor
(or ARB) is not effective in controlling pressure, it still may
be used with other antihypertensive drugs for its vascular,
myocardial and renal protective actions.
Myocardial infarction. One important and well-accepted
indication for use of beta-blockers (specifically those with-
out intrinsic sympathomimetic activity) is prevention of a
second MI (49–51). Much has been written recently about
the insufficient use of these agents for this purpose (59).
This is particularly important in hypertensive patients fol-
lowing MI and does not preclude administration with ACE
inhibitors because of drug interaction (1). The JNC-6
suggests that the use of ACE inhibitors after MI should be
restricted to those patients with only systolic dysfunction.
However, their value after MI was assessed in patients with
fairly normal systolic dysfunction, and they prevented death,
second infarction and subsequent cardiac failure (56–58).
Diastolic dysfunction in hypertension has become more
common, particularly in the elderly or in patients with
ischemic heart disease (60); both situations are associated
with increased ventricular collagen (61). Angiotensin con-
verting enzyme inhibitors provide particular promise in
those patients because of their potential to reduce fibrosis
(62–64).
Cardiac failure. JNC-6 specifically advocates ACE inhib-
itors, alone or with diuretics, in cardiac failure, but two
points were not discussed. First, we reiterate the observation
that ACE-inhibitors are not administered often enough and
in inadequate doses (65). Establishing optimal dosing is
more difficult for normotensive individuals in whom the end
point of pressure reduction is not utilized. Second, when
ACE inhibitors are prescribed for hypertensive patients,
maximally effective doses of the ACE inhibitor (or ARB)
may not be sufficient to control pressure. In that event, they
may be used with another drug class, provided the addi-
tional agent does not adversely effect ventricular function.
Isolated systolic hypertension. Specific concerns have
been raised about the so-called J-curve, particularly in
patients with ischemic heart disease. Discussion of this is
useful in the context of isolated systolic hypertension and
patients with lesser elevated diastolic pressure. Inherent in
this hypothesis is potential risk of coronary events when
arterial pressure is reduced excessively in patients with
CHD because the diastolic pressure is responsible for
myocardial perfusion (66). Earlier support of this phenom-
enon was provided by retrospective studies (67,68). How-
ever, recent data from prospectively controlled trials, involv-
ing patients with and without hypertension, have failed to
support these concerns. One group of studies, conducted in
patients with isolated systolic hypertension in the elderly,
used diuretics, beta-blockers, and a calcium antagonist
(24,69–71). None demonstrated increased coronary events.
Diastolic pressure, originally less than 90 to 95 mm Hg, was
reduced further without provoking coronary events. Fur-
thermore, even in those studies that involved primarily
normotensive individuals following MI, the ACE inhibitors
reduced diastolic pressure and decreased coronary events
(56–58). More recently, a dihydropyridine calcium antago-
nist (nitrendipine) was employed for elderly patients with
isolated systolic hypertension and demonstrated significant
protection from fatal and nonfatal strokes; there was no
increase in coronary events even though diastolic pressure
was reduced (71).
Finally, the J-shape curve was not detected in the Hy-
pertension Optimal Treatment (HOT) trial, in which
another dihydropyridine calcium antagonist (felodipine) was
used (72). This study was designed specifically to lower
diastolic pressure progressively in three groups of patients.
An additional finding of this study was the safety of aspirin
therapy in cardiovascular protection, and there were no
bleeding episodes. Hence, in considering treatment of
patients with either isolated systolic hypertension in the
elderly or to reduce diastolic pressures below 80 mm Hg, no
increased coronary events or J-shape curve were demon-
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strated. Therefore, the JNC-6 recommendation for diuretics
or long-acting dihydropyridine calcium antagonists seems
appropriate in elderly patients with isolated systolic hyper-
tension.
Diabetes (type 1) with proteinuria. As presented in
JNC-6, hypertensive patients with type-1 diabetes should be
considered for special treatment. The most important ther-
apeutic recommendation in these patients is that a goal
pressure (,130/,85 or lower, 125/75 mm Hg) based on
several large prospective studies (73–77) must be estab-
lished. This pressure goal is safe with respect to CHD as
noted previously. Furthermore, there were recommenda-
tions to use diuretics in low dosages and beta-blockers with
particular care because these latter agents may mask symp-
toms of hyperinsulinism. Finally, the ACE inhibitors were
recommended for this compelling reason, but I believe that,
in some instances, ARBs and certain calcium antagonists
should also be considered. Before discussing the rationale
for these comments, brief discussion is necessary to explain
the intrarenal hemodynamic alterations in diabetes that
mandate reconsideration of therapy.
First, we must appreciate that, whereas antihypertensive
therapy with diuretics and beta-blockers had been associated
with reduced morbidity and mortality from stroke and
CHD, during these years the numbers of hypertensive
patients progressing into end stage renal disease (ESRD)
continued to increase unabatedly (78). Nephrologists have
not explained adequately why this occurs, but several rea-
sons have been offered. First, antihypertensive therapy had
not lowered pressure sufficiently to stop, reverse and prevent
ESRD. Second, the antihypertensive therapy that was
available did not prevent ESRD or, according to therapeutic
nihilists, drug therapy (in general) will not prevent ESRD.
Third, and perhaps most important, other classes of anti-
hypertensive drugs yet to be developed may possess different
modes of action that will prevent ESRD. To be sure, certain
lines of evidence have strongly suggested that goal pressures
were not low enough to prevent ESRD (73–77). Further-
more, it is also probably true that the earlier classes were not
specific enough in action to reverse the intrarenal hemody-
namic alterations. Indeed, in experimental studies with
diuretics alone, nephrosclerosis progressed pathophysiologi-
cally (53,79).
At this point, it is appropriate to describe the intrarenal
hemodynamic derangements associated with progression to
ESRD. These alterations are manifested by renal ischemia
and increased glomerular hydrostatic pressure that promotes
protein ultrafiltration and ultimate development of glomer-
ular sclerosis (53,80). It is now clear that the ACE inhibi-
tors (and probably ARBs) increase renal blood flow while
reducing glomerular hydrostatic pressure through dilation of
both afferent and efferent glomerular arterioles (74,81–84).
Unfortunately, general thinking has suggested that the
calcium antagonists, which also increase renal flow and
produce afferent glomerular arteriolar dilation, are inappro-
priate for this therapeutic mission because they do not dilate
efferent arterioles. Although this may be so for some
calcium antagonists, it is not so for all (85). This class of
drugs is highly heterogeneous and some agents are appro-
priate for treating hypertensive patients with renal involve-
ment.
Angiotensin converting enzyme inhibitors have now been
tested for prevention of ESRD. Because hypertensive pa-
tients with diabetes mellitus, or who are black, are the most
susceptible to progression to ESRD, the first controlled
multicenter studies involved these patients with type 1
diabetes. These studies demonstrated that ACE inhibitors
reduced proteinuria, prevented further impairment of renal
function and prevented (or retarded) development of ESRD
(86–88). Other studies in hypertensive diabetics (type 2)
have demonstrated similar findings (77). Still other reports
have demonstrated improvement in nondiabetic hyperten-
sive patients (86–88). Finally, several studies are in progress
concerned with black essential hypertensive patients and
others with type 2 diabetes (89,90).
Other compelling renal indications. Thus, the JNC-6
recommendations are appropriate:
1) pressure should be reduced to a lower goal (,130/
,85 mm Hg or lower);
2) diuretics should be used in low dosages; and
3) treatment of patients with hypertension and type 1
diabetes should include ACE inhibitors.
However, I believe these recommendations do not go far
enough. Thus, patients with type 2 diabetes and proteinuria,
with or without impaired renal function, should be treated
similarly. Furthermore, meaningful studies must be de-
signed to demonstrate efficacy of ACE inhibitors and ARBs
in nondiabetic hypertensives (with essential hypertension)
having proteinuria and impaired renal function. These
patients include a very important segment of the hyperten-
sive population with proteinuria who are at great risk for
progression to ESRD.
But what about the calcium antagonists? Several calcium
antagonists have been shown to experimentally and clini-
cally reduce glomerular hydrostatic pressure and to dilate
both efferent as well as afferent glomerular arterioles (e.g.,
diltiazem, nitrendipine, felodipine) (85,91–94). But the
clinical information has been clouded by findings that have
shown that the ACE inhibitors may be preferable to
calcium antagonists. In one study, diabetic hypertensives
had less progressive renal disease with enalapril than with
nisoldipine, and patients treated with nisoldipine had more
nonfatal cardiovascular complications (95). Many inferred
from this study that calcium antagonists should not be used
in ESRD. In truth, because cardiac involvement from
hypertension is already present, once renal involvement
from hypertension occurs (19), it may be wise to use both an
ACE inhibitor and a specific calcium antagonist. The issue
may not simply be either one class of drugs versus the other.
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Furthermore, and most important, if there is evidence of
bilateral occlusive renal arterial disease (in which ACE
inhibitors are contraindicated), certain calcium antagonists
may be preferable. Thus, we conclude that there is ample
evidence to suggest that, in addition to patients with
hypertension and type I diabetes mellitus, other patients at
risk for ESRD should also be treated with additional classes
of agents.
Miscellaneous compelling considerations. Considerable
discussion has been generated about ideal antihypertensive
drugs for patients with hyperlipidemia. All classes may be
considered “lipid neutral” although short-term treatment
with thiazides may elevate LDL cholesterol and beta-
blockers may reduce HDL cholesterol. The alpha-
adrenergic receptor blockers have been recommended for
reducing cholesterol (but this has not been demonstrated for
FDA approval). However, this latter class of agents is of
value in men with benign prostatic hyperplasia and hyper-
tension, distinctly for possible treatment of both diseases.
The thiazides may also be useful in osteoporosis and in
certain renal calculi. Calcium antagonists are of value in
some patients with supraventricular tachycardia (i.e., vera-
pamil, diltiazem), cyclosporin-associated hypertension and
migraine headaches. Adrenergic inhibitors (including beta-
blockers) are of value in patients with hyperthyroidism,
hyperdynamic beta-adrenergic circulatory state and inten-
tion tremor.
CONCLUDING REMARKS
Treatment of hypertension over the past four decades has
been a remarkable story of evolution: evolution in our
understanding of the pathophysiology of the disease that is
associated with an inextricable evolution in the development
of newer drugs. These two areas of medical progress have
dramatically altered the management of patients with hy-
pertensive diseases as well as other diseases previously
unsuccessfully treated. Thus, prevalence of hypertensive
emergencies has dramatically diminished; deaths from
stroke and CHD have remarkably improved, and means to
prevent the emergence of hypertension primarily are now
established. Nevertheless, numbers of hypertensive patients
with cardiac failure and with ESRD are progressively
increasing. Thus, in the early 1970s, hypertension was the
most common cause of cardiac failure (96); it remains so
today (97). In those earlier years, patients with ESRD and
hypertension were less numerous, probably because patients
succumbed to earlier occurring complications of hyperten-
sion. More specific therapeutic means to deal with, and
perhaps prevent, these target organ complications are now
available. However, the most effective means of preventing
these unwanted outcomes of hypertension have been avail-
able for some time: early recognition of hypertension,
immediate treatment of the earliest manifestations of the
slightest elevations of systolic as well as diastolic pressure
and prompt recognition of the earliest clinical manifesta-
tions of target organ involvement.
To say that we have been doing a good job with early
recognition and treatment of Stages 1 and 2 hypertension is
contrary to the facts. The truth is that we are witnessing a
reversal of our earlier gains. This can be changed; this must
be changed. Thus, the best means of achieving and sustain-
ing new gains is prompt recognition of the earliest stages of
hypertension and our immediate and continued intervention
to control what heretofore has been termed “mild” hyper-
tension. If we continue to perceive these evidences of early
hypertensive disease as “mild,” the most common diagnoses
of hospitalizations and morbidity (e.g., cardiac failure and
ESRD) will continue to adversely affect our population and
our economy.
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